Cash generated from the ‘faster to market’ personal care products will assist in funding pharmaceutical opportunities to a stage where a rewarding partnership/license agreement can be negotiated.
“Our personal care division is consistently growing, providing multiple opportunities for Phosphagenics which are low-risk.” As such “I can say that we are truly a low-risk company.”
The strength of Phosphagenics business “is the versatility of our technology, acting as a competitive advantage for us,” as the company operates alongside 42 other of pharmaceutical companies. “Essentially it can be delivered in a gel, patch or spray form.”
What does she mean by the above and why was this not elaborted upon in a newsletter. This is what investors need to know. PoS.
- Forums
- ASX - By Stock
- parathyroid hormone.
Cash generated from the ‘faster to market’ personal care...
Featured News
Add AVE (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $205 | 72.91K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
62 | 90468113 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 61728026 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
62 | 90468113 | 0.002 |
22 | 73500009 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 61728026 | 18 |
0.004 | 22093142 | 20 |
0.005 | 20469333 | 10 |
0.006 | 20865067 | 11 |
0.007 | 10865221 | 9 |
Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |